Midwest Heart and Vascular Spec
Welcome,         Profile    Billing    Logout  
 4 Trials 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bloom, Stephen
WARRIOR, NCT03417388: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD

Active, not recruiting
4
2476
US
High dose potent statin, atorvastatin or rosuvastatin, ACE-I (lisinopril) or ARB (losartan), ACE-I or ARB, Aspirin, Lifestyle Counseling, PACE Lifestyle Intervention, Quality of Life Questionnaires, QOL
University of Florida, United States Department of Defense
Coronary Artery Disease
09/24
12/24
V-PLAQUE, NCT05360446: Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Coronary Artery Disease
01/27
01/27
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17006
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27
NCT06018194: ELUCIDATE FFRct Study

Recruiting
N/A
350
US
ElucidVivo
Elucid Bioimaging Inc., Lundquist Institute at Harbor-UCLA Medical Center
Coronary Artery Disease
07/24
07/24
NCT01945840: Gut Hormones and Roux en Y Gastric Bypass

Recruiting
N/A
190
Europe
Roux en Y Gastric Bypass Surgery, Gut hormone infusion, Placebo infusion, Very low calorie diet
Imperial College London
Obesity, Type 2 Diabetes
10/28
10/28
Covalesky, John
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease

Active, not recruiting
3
17006
Europe, Canada, Japan, US, RoW
Inclisiran sodium 300 mg, Placebo
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease
10/27
10/27

Download Options